Private equity firm CVC Capital Partners is exploring a sale of Arthea, the personal care company behind the Dr. Teal's brand, in a deal that could value the business at roughly $2 billion, according to a Reuters report.
Reuters, citing people familiar with the matter, said CVC has hired investment banks Moelis & Company and William Blair to run an early-stage sale process for Arthea, which was formerly known as PDC Brands. The process is still in its infancy, and there is no guarantee it will result in a sale, the report noted.
What is Arthea?
Arthea is a mass-market personal care platform that owns a portfolio of well-known drugstore and supermarket brands. In addition to Dr. Teal's, a popular line of bath salts and body care products, the company's brands include Bodycology, Body Fantasies, BOD Man, and Cantu, a textured hair care line. Arthea says its products are sold in more than 90 countries, though the bulk of its business is in North America.
CVC acquired the company, then known as PDC Brands, from private equity firm Yellow Wood Partners in 2017 for $1.43 billion. Since then, CVC has looked to grow the business, and a sale at around $2 billion would represent a meaningful increase in value from the original purchase price.
Why is CVC selling?
Private equity firms typically hold investments for a set period—often five to seven years—before looking for an exit. CVC has owned Arthea for more than seven years, so a sale would be a natural next step. The firm may also be looking to return capital to its investors, or it could be seeking to take advantage of strong demand for consumer brands with steady cash flows.
Consumer personal care companies have been attractive targets for both strategic buyers and other private equity firms. These businesses tend to generate predictable revenue, have loyal customer bases, and are less exposed to economic cycles than many other sectors. That makes them appealing to investors looking for stable returns.
The potential sale comes at a time when small business optimism has slipped as owners keep a close eye on the broader economy, but larger consumer brands have continued to attract interest from buyers.
What does this mean for investors?
For everyday investors, this news is mostly a signal about the state of the private equity market and consumer brand valuations. Arthea is not publicly traded, so individual investors cannot directly buy or sell its stock. However, the potential $2 billion price tag offers a glimpse into how much private investors are willing to pay for well-known consumer brands.
If the sale goes through, it could also have a ripple effect on the broader personal care sector. A successful sale at that valuation might encourage other private equity firms to look at similar companies, potentially driving up prices for other consumer brands. Conversely, if the sale falls through or fetches a lower price, it could signal that the market for such assets is cooling.
For investors who hold shares in publicly traded personal care companies, the news is a reminder that brand strength and market position remain key drivers of value. Companies with strong, recognizable brands like Dr. Teal's often command premium valuations, whether they are owned by private equity or public shareholders.
What to watch next
The sale process is still early, and several factors could influence the outcome. The final price will depend on the level of interest from potential buyers, which could include other private equity firms, large consumer goods companies, or even international players looking to expand in the U.S. market.
Investors should also keep an eye on how the broader economy affects the deal. Interest rates, consumer spending, and the availability of financing all play a role in how much buyers are willing to pay. In a higher-rate environment, buyers may be more cautious, which could pressure valuations.
For now, the news is a reminder that private equity firms are actively looking to cash in on consumer brands. Similar moves have been seen recently, such as Spire Healthcare's £1.03bn buyout and Armani's plan to sell a 15% stake. These deals highlight the ongoing appetite for established businesses with strong brand recognition.
As the Arthea sale process develops, investors will be watching to see who steps forward and at what price. A deal at $2 billion would mark a solid return for CVC, and it would underscore the enduring value of everyday personal care products that millions of people use without a second thought.
